FDA APPROVES MERCK’S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA

Del and Jefferey dive into the troubling numbers behind Merck’s new RSV shot for infants, recently greenlit by the FDA. Trial data revealed higher rates of deaths and severe respiratory illness in vaccinated babies, yet the FDA overlooked this concerning trial data.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.